Meropenem warnings: Difference between revisions
(Created page with "__NOTOC__ {{Meropenem}} {{CMG}} ==Warnings== Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy wit...") |
No edit summary |
||
| Line 16: | Line 16: | ||
C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require [[colectomy]]. CDAD must be considered in all patients who present with [[diarrhea]] following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. | C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require [[colectomy]]. CDAD must be considered in all patients who present with [[diarrhea]] following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. | ||
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated. | If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.<ref>{{Cite web | last = | first = |title = http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050706s022lbl.pdf | url =http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050706s022lbl.pdf | publisher = |date = | accessdate = }}</ref> | ||
==References== | |||
{{Reflist}} | |||
{{FDA}} | |||
[[Category:Antibiotics]] | |||
[[Category:Wikinfect]] | |||
Revision as of 22:10, 20 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Warnings
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with β-lactams. These reactions are more likely to occur in individuals with a history of sensitivity to multiple allergens.
There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe hypersensitivity reactions when treated with another β-lactam. before initiating therapy with merrem i.v., careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, other β-lactams, and other allergens. If an allergic reaction to merrem i.v.occurs, discontinue the drug immediately. serious anaphylactic reactions require immediate emergency treatment with epinephrine,oxygen, intravenous steroids, and airway management, including intubation. Other therapy may also be administered as indicated.
Seizures and other CNS adverse experiences have been reported during treatment with MERREM I.V. (See PRECAUTIONS and ADVERSE REACTIONS.)
Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including MERREM I.V., and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.[1]
References
- ↑ "http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050706s022lbl.pdf" (PDF). External link in
|title=(help)
Adapted from the FDA Package Insert.